Email
Print
Biliary Tumor Market Overview:
The Biliary Tumor Market size is estimated to reach $6.1 Billion by 2030, growing at a CAGR of 5.7% during the forecast period 2024-2030. A combination of rising incidence rates, advances in medical technology and enhanced focus on personalized treatment options are the main drivers in the biliary tumor market. The increased rate of biliary duct cancer is driving demand for novel treatment solutions. Diagnostic technologies including MRI, PET/CT scans and molecular diagnostics are key drivers of market growth, due to their advances in earlier detection and better planning of treatment.
The increasing adoption of targeted therapies like HER2 and FGFR inhibitors in conjunction with immunotherapies (antiPD1 checkpoint inhibitors) are driving personalized care options and improving patient disease control. Because of their reduced recovery time and lower rates of complications, minimally invasive treatment approaches including radiofrequency ablation (RFA) and biliary stenting are also becoming increasingly popular. At the same time, higher cancer incidence is being fueled by a growing aging population, mainly in developed regions, as well as growing healthcare spending in emerging markets and favorable reimbursement policies boosting accessibility to advanced therapies. All these factors together are driving growth in the biliary tumor market.
Market Snapshot:
Biliary Tumor Market - Report Coverage:
The “Biliary Tumor Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Biliary Tumor Market.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COVID-19 / Ukraine Crisis - Impact Analysis:
• The biliary tumor market was disrupted by the COVID 19 pandemic due to restrictions on non-urgent medical services, which delayed diagnoses and treatments. Since hospitals decided to focus on COVID cases, many surgeries and chemo sessions were put on hold. New therapies were delayed by the postponement of clinical trials. Also, diagnostic tool and cancer drug availability was also affected by disruptions in supply chain, slowing down market growth temporarily.
• The Russia Ukraine war affected the biliary tumor market due to supply chain disruptions, especially in the Eastern European market. The war decreased healthcare budgets with the economic impact leading to less investments in new, more advanced therapies and the longer wait to take up newer treatment solutions.
Key Takeaways:
North America Leads the Market
The Biliary Tumor Market is led in North America by several key factors, including presence of a prominent set of research institutions, widespread access to advanced healthcare infrastructure and healthcare spending. This is further boosted by the high prevalence of biliary tumors in the region. Biliary Tract Cancer affects around 10000 Americans a year, according to the Dana-Farber Cancer Institute, which means there is a huge need for effective treatments and therapies. Furthermore, the strength of cancer research in North America, along with government support of research of cancer, hastens the appearance of cutting-edge diagnostic tools and treatment options. Advancement of imaging techniques also brings the region a higher rate of early diagnosis, resulting into a higher rate of patient outcome and as a result market growth. In addition, the region dominates the biliary tumor market owing to the presence of many leading pharmaceutical companies and constant clinical trials, with new therapies and treatment approaches being introduced.
Surgery is the largest segment
The most common treatment for biliary tumors is surgery because it offers the best chance of cure, particularly when the tumor can be fully removed. As per the Cleveland Clinic, procedures such as liver resection or biliary bypass surgery are done and thousands of people have successful cholecystectomies each year with most having no complications or side effects. Surgical techniques have become more minimally invasive and recovery has been easier and quicker. Also, according to Top Doctor UK, the percentage of patients with bile duct tumors that are eligible for surgical resection varies by tumor location, from 15% to 50%. Those with tumors close to the lower bile duct, which joins the intestine, have a better chance for surgery. A 5-year survival rate of 30% to 40% is achievable if the tumor is fully removed and surgery is the primary treatment.
MRCP to grow the fastest
Magnetic Resonance Cholangiopancreatography (MRCP) is becoming one of the fastest growing diagnostic methods in the biliary tumor market because of its non-invasive nature and better imaging. MRCP produces clear, detailed images of organs and bile ducts without exposing patients to X-ray radiation, the Cleveland Clinic reports. This specialized MRI uses radiofrequency waves, a powerful magnetic field and computer processing to create highly accurate images of the organs, making it safer for many patients. MRCP is a benefit in repeated diagnostic procedures because unlike traditional imaging methods, MRCP does not involve the risk of radiation exposure. Its ability to give precise visualization without invasive techniques makes it popular.
Rising Biliary Duct Cancer Cases Drives the Market
The rising incidence of biliary duct cancer, especially intrahepatic cholangiocarcinoma, drives the Biliary Tumor Market. The need for effective diagnostics and treatment solutions for this rare but aggressive form of cancer is growing as the prevalence of it increases. The incidence of intrahepatic cholangiocarcinoma has been rising steadily in the Western world, according to the American Society of Clinical Oncology Educational Book. In these 30 years, countries such as United Kingdom, the United States, have seen a rise from 0.01 case per to 0.06 case per 100,000 people. Hence, there is greater attention of health care providers, pharmaceutical companies and research institutions which have resulted in advent of pharmaceutics, and early detection methods and special treatment. The increasing number of cases and the requirement for improved patient outcomes and disease management also contributes to market growth. The biliary duct cancer solutions market will expand greatly as resources are channelled towards addressing this trend.
Low Survival Rate to Hamper the Market
Low survival rates of bile duct cancer pose one of the most serious challenges of the biliary tumor market, as it has a direct impact on treatment outcomes and, thus, market dynamics. Medical News Today reports the 5-year relative survival rate for bile duct cancers originating within the liver varies between 2% and 24%, and those originating outside the liver are even worse, with rates between 2% and 17%. These poor prognoses show the disease's aggressiveness and ineffectiveness of current treatments, making it hard to improve patient outcomes. Diagnosing bile duct cancer at early stages is complicated by its complexity and limited number of effective therapies. Consequently, the market is under great pressure to introduce better diagnostic tools and treatment options. Long term survival and optimization of therapeutic approaches is critically dependent on the ability to overcome these challenges.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the Biliary Tumor Market. The top 10 companies in this industry are listed below:
1. Taiho Oncology
2. AbbVie Inc.
3. Eli Lilly & Company
4. Merck KGaA
5. AstraZeneca
6. Helsinn Group
7. Bayer AG
8. F. Hoffmann-La Roche AG
9. Fresenius SE & Co. KGaA
10. Pfizer Inc.
Scope of the Report:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. Biliary Tumor Market - Overview
1.1 Definitions and Scope
2. Biliary Tumor Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Biliary Tumor Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Biliary Tumor Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Biliary Tumor Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Biliary Tumor Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Biliary Tumor Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Biliary Tumor Market - By Product Type(Market Size -$Million / $Billion)
8.1 Market Size and Market Share Analysis
8.2 Application Revenue and Trend Research
8.3 Product Segment Analysis
9. Biliary Tumor Market - By Type(Market Size -$Million / $Billion)
9.1 Clinical Trials Segmentation- by Phase
9.1.1 Phase III Product Candidates
9.1.2 Phase II Product Candidates
9.1.3 Phase I Product Candidates
9.2 Clinical Trials Segmentation- by Status
9.2.1 Suspended
9.2.2 Terminated
9.2.3 Withdrawn
9.2.4 Ongoing
9.2.5 Completed
9.2.6 Other Statuses
10. Biliary Tumor - By Application Type(Market Size -$Million / $Billion)
10.1 Segment type Size and Market Share Analysis
10.2 Application Revenue and Trends by type of Application
10.3 Application Segment Analysis by Type
11. Biliary Tumor- By Geography (Market Size -$Million / $Billion)
11.1 Biliary Tumor Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Biliary Tumor- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Biliary Tumor- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Biliary Tumor - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Biliary Tumor - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Biliary Tumor Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Biliary Tumor Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Biliary Tumor Market - Key Company List by Country Premium
15. Biliary Tumor Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Company 2
15.3 Company 3 & More
*Financials would be provided on a best efforts basis for private companies
16. Biliary Tumor Market - Appendix
16.1 Abbreviations
16.2 Sources
17. Biliary Tumor Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends
LIST OF TABLES
1.Global Clinical Trials Segmentation- by Phase Market 2023-2030 ($M)
1.1 Phase III Product Candidates Market 2023-2030 ($M) - Global Industry Research
1.2 Phase II Product Candidates Market 2023-2030 ($M) - Global Industry Research
1.3 Phase I Product Candidates Market 2023-2030 ($M) - Global Industry Research
2.Global Clinical Trials Segmentation- by Status Market 2023-2030 ($M)
2.1 Suspended Market 2023-2030 ($M) - Global Industry Research
2.2 Terminated Market 2023-2030 ($M) - Global Industry Research
2.3 Withdrawn Market 2023-2030 ($M) - Global Industry Research
2.4 Ongoing Market 2023-2030 ($M) - Global Industry Research
2.5 Completed Market 2023-2030 ($M) - Global Industry Research
3.Global Clinical Trials Segmentation- by Phase Market 2023-2030 (Volume/Units)
3.1 Phase III Product Candidates Market 2023-2030 (Volume/Units) - Global Industry Research
3.2 Phase II Product Candidates Market 2023-2030 (Volume/Units) - Global Industry Research
3.3 Phase I Product Candidates Market 2023-2030 (Volume/Units) - Global Industry Research
4.Global Clinical Trials Segmentation- by Status Market 2023-2030 (Volume/Units)
4.1 Suspended Market 2023-2030 (Volume/Units) - Global Industry Research
4.2 Terminated Market 2023-2030 (Volume/Units) - Global Industry Research
4.3 Withdrawn Market 2023-2030 (Volume/Units) - Global Industry Research
4.4 Ongoing Market 2023-2030 (Volume/Units) - Global Industry Research
4.5 Completed Market 2023-2030 (Volume/Units) - Global Industry Research
5.North America Clinical Trials Segmentation- by Phase Market 2023-2030 ($M)
5.1 Phase III Product Candidates Market 2023-2030 ($M) - Regional Industry Research
5.2 Phase II Product Candidates Market 2023-2030 ($M) - Regional Industry Research
5.3 Phase I Product Candidates Market 2023-2030 ($M) - Regional Industry Research
6.North America Clinical Trials Segmentation- by Status Market 2023-2030 ($M)
6.1 Suspended Market 2023-2030 ($M) - Regional Industry Research
6.2 Terminated Market 2023-2030 ($M) - Regional Industry Research
6.3 Withdrawn Market 2023-2030 ($M) - Regional Industry Research
6.4 Ongoing Market 2023-2030 ($M) - Regional Industry Research
6.5 Completed Market 2023-2030 ($M) - Regional Industry Research
7.South America Clinical Trials Segmentation- by Phase Market 2023-2030 ($M)
7.1 Phase III Product Candidates Market 2023-2030 ($M) - Regional Industry Research
7.2 Phase II Product Candidates Market 2023-2030 ($M) - Regional Industry Research
7.3 Phase I Product Candidates Market 2023-2030 ($M) - Regional Industry Research
8.South America Clinical Trials Segmentation- by Status Market 2023-2030 ($M)
8.1 Suspended Market 2023-2030 ($M) - Regional Industry Research
8.2 Terminated Market 2023-2030 ($M) - Regional Industry Research
8.3 Withdrawn Market 2023-2030 ($M) - Regional Industry Research
8.4 Ongoing Market 2023-2030 ($M) - Regional Industry Research
8.5 Completed Market 2023-2030 ($M) - Regional Industry Research
9.Europe Clinical Trials Segmentation- by Phase Market 2023-2030 ($M)
9.1 Phase III Product Candidates Market 2023-2030 ($M) - Regional Industry Research
9.2 Phase II Product Candidates Market 2023-2030 ($M) - Regional Industry Research
9.3 Phase I Product Candidates Market 2023-2030 ($M) - Regional Industry Research
10.Europe Clinical Trials Segmentation- by Status Market 2023-2030 ($M)
10.1 Suspended Market 2023-2030 ($M) - Regional Industry Research
10.2 Terminated Market 2023-2030 ($M) - Regional Industry Research
10.3 Withdrawn Market 2023-2030 ($M) - Regional Industry Research
10.4 Ongoing Market 2023-2030 ($M) - Regional Industry Research
10.5 Completed Market 2023-2030 ($M) - Regional Industry Research
11.APAC Clinical Trials Segmentation- by Phase Market 2023-2030 ($M)
11.1 Phase III Product Candidates Market 2023-2030 ($M) - Regional Industry Research
11.2 Phase II Product Candidates Market 2023-2030 ($M) - Regional Industry Research
11.3 Phase I Product Candidates Market 2023-2030 ($M) - Regional Industry Research
12.APAC Clinical Trials Segmentation- by Status Market 2023-2030 ($M)
12.1 Suspended Market 2023-2030 ($M) - Regional Industry Research
12.2 Terminated Market 2023-2030 ($M) - Regional Industry Research
12.3 Withdrawn Market 2023-2030 ($M) - Regional Industry Research
12.4 Ongoing Market 2023-2030 ($M) - Regional Industry Research
12.5 Completed Market 2023-2030 ($M) - Regional Industry Research
13.MENA Clinical Trials Segmentation- by Phase Market 2023-2030 ($M)
13.1 Phase III Product Candidates Market 2023-2030 ($M) - Regional Industry Research
13.2 Phase II Product Candidates Market 2023-2030 ($M) - Regional Industry Research
13.3 Phase I Product Candidates Market 2023-2030 ($M) - Regional Industry Research
14.MENA Clinical Trials Segmentation- by Status Market 2023-2030 ($M)
14.1 Suspended Market 2023-2030 ($M) - Regional Industry Research
14.2 Terminated Market 2023-2030 ($M) - Regional Industry Research
14.3 Withdrawn Market 2023-2030 ($M) - Regional Industry Research
14.4 Ongoing Market 2023-2030 ($M) - Regional Industry Research
14.5 Completed Market 2023-2030 ($M) - Regional Industry Research
LIST OF FIGURES
1.US Biliary Tumor Market Revenue, 2023-2030 ($M)
2.Canada Biliary Tumor Market Revenue, 2023-2030 ($M)
3.Mexico Biliary Tumor Market Revenue, 2023-2030 ($M)
4.Brazil Biliary Tumor Market Revenue, 2023-2030 ($M)
5.Argentina Biliary Tumor Market Revenue, 2023-2030 ($M)
6.Peru Biliary Tumor Market Revenue, 2023-2030 ($M)
7.Colombia Biliary Tumor Market Revenue, 2023-2030 ($M)
8.Chile Biliary Tumor Market Revenue, 2023-2030 ($M)
9.Rest of South America Biliary Tumor Market Revenue, 2023-2030 ($M)
10.UK Biliary Tumor Market Revenue, 2023-2030 ($M)
11.Germany Biliary Tumor Market Revenue, 2023-2030 ($M)
12.France Biliary Tumor Market Revenue, 2023-2030 ($M)
13.Italy Biliary Tumor Market Revenue, 2023-2030 ($M)
14.Spain Biliary Tumor Market Revenue, 2023-2030 ($M)
15.Rest of Europe Biliary Tumor Market Revenue, 2023-2030 ($M)
16.China Biliary Tumor Market Revenue, 2023-2030 ($M)
17.India Biliary Tumor Market Revenue, 2023-2030 ($M)
18.Japan Biliary Tumor Market Revenue, 2023-2030 ($M)
19.South Korea Biliary Tumor Market Revenue, 2023-2030 ($M)
20.South Africa Biliary Tumor Market Revenue, 2023-2030 ($M)
21.North America Biliary Tumor By Application
22.South America Biliary Tumor By Application
23.Europe Biliary Tumor By Application
24.APAC Biliary Tumor By Application
25.MENA Biliary Tumor By Application
The Biliary Tumor Market is projected to grow at 5.7% CAGR during the forecast period 2024-2030.
The Biliary Tumor Market size is estimated to be $4.1 Billion in 2023 and is projected to reach $6.1 Billion by 2030
The leading players in the Biliary Tumor Market are Taiho Oncology, AbbVie Inc., Eli Lilly & Company, Merck KGaA, AstraZeneca and Others.